Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Kaposi sarcoma

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers Doxil/Caelyx BE Study Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma HHV8 and Solid Organ Transplantation Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Pomalidomide Treatment in Patients With Kaposi Sarcoma Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi’ s Sarcoma Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Assessment of Blood Vessel Density in Kaposi s Sarcoma Lesions Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma History of the KSHV Inflammatory Cytokine Syndrome (KICS) Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi’s Sarcoma and Lymphatic Drainage by SPECT/CT Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi’s Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi’s Sarcoma Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine Anti-Retrovirals for Kaposi’s Sarcoma Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi’s Sarcoma A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi’s Sarcoma Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT sEphB4-HSA in Treating Patients With Kaposi Sarcoma A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi’s Sarcoma A Phase II Trial of COL-3 in Patients With HIV Related Kaposi’s Sarcoma NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi’s Sarcoma in Zimbabwe Bevacizumab to Treat Kaposi’s Sarcoma in HIV-Positive and HIV-Negative Patients Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi’s Sarcoma Interleukin-12 in Treating Patients With AIDS-Related Kaposi’s Sarcoma Suppression of Oral HHV8 Shedding With Valganciclovir Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi’s Sarcoma A Study of sEphB4-HSA in Kaposi Sarcoma Lenalidomide in Treating Patients With AIDS-Associated Kaposi’s Sarcoma Trial of Ixazomib for Kaposi Sarcoma Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe Pomalidomide for Kaposi Sarcoma in People With or Without HIV Risk Factors for Non-HIV-Related Kaposi s Sarcoma Effects of Maraviroc (MVC) on HIV-related Kaposi’s Sarcoma (KS) A Study of Selumetinib in Patients With Kaposi’s Sarcoma Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi’s Sarcoma Development of Serologic Assays for Human Herpes Virus-8 Studies of Human Herpesvirus 8 and Kaposi’s Sarcoma in Sicily Smartphone Confocal Microscopy for Diagnosing Kaposi’s Sarcoma